Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Uncertainty exists regarding the prevalence and clinical features associated with the practice of polypharmacy in bipolar disorder (BD), warranting a systematic review on the matter. METHODS: Three authors independently searched major electronic databases from inception till September 2015. Articles were included that reported either qualitative or quantitative data about the prevalence and clinical features associated with polypharmacy in adult cases of BD. RESULTS: The operative definitions of polypharmacy adopted across varying studies varied, with concomitant use of two or more psychotropic medications or use of four or more psychotropic medications at once being the most common and the most reliable, respectively. Regardless of type or current mood episode polarity of BD, prevalence rates up to 85% and 36% were found using the most permissive (two or more medications at once) and the most conservative (four or more) operative definitions for polypharmacy, respectively. Point prevalence prescription rates of one or more antidepressant or antipsychotic as part of a polypharmacy regimen occurred in up to 45% or 80% of the cases, respectively, according to the most permissive definition of polypharmacy. In contrast, lithium prescription rates ranged from 13% to 33% in BD patients receiving polypharmacy according to conservative and permissive definitions, possibly suggesting a reduced need for augmentation of combination strategies for those cases of BD with a favorable lifetime lithium response and/or long-lasting treatment as well as less likelihood of lithium response over the time most severe cases possibly exposed to a more complex polypharmacy overall. LIMITATIONS: "Apples and oranges" bias; publication bias for most recently introduced compounds. CONCLUSION: Polypharmacy is common among people with BD across varying type and mood episode phases of illness. Special population, including BD patients at high risk of familial load for suicidal behavior, solicit further research as well as the plausible "protective" role of lithium toward polypharmacy in BD. The PROSPERO registration number is CRD42014015084.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015) · World Psychiatry · doi:10.1002/wps.20204 · Cited by 820 · cited 1×
“Antipsychotic drugs prescription rates and polypharmacy in BD The evidence about the use of antipsychotic polypharmacy in BD is also scarce and prone to publication bias considering the relatively novel introduction of most SGA drugs or their latter approval for BD and/or popularity as off-label prescriptions for BD p…”
Perlis, R. H., Ostacher, M. J., Patel, J. K., Marangell, L. B., Zhang, H., Wisniewski, S. R., Ketter, T. A., Miklowitz, D. J., Otto, M. W., Gyulai, L., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.217 · Cited by 689 · cited 1×
“This reflects the findings from the most comprehensive “real-world” pharmacological trial on BD patients to date, the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD),(10) in which up to 42% of the symptomatic patients included at baseline did not achieve recovery within 2 years of follow-up, de…”
Psychiatric and Medical Comorbidities of Bipolar Disorder
Krishnan, K. R. R. (2005) · Psychosomatic Medicine · doi:10.1097/01.psy.0000151489.36347.18 · Cited by 502 · cited 1×
“41 Concordant with previous reports, 58,59 additional analyses carried out by Weinstock et al 27 revealed that the average number of prescriptions almost doubled (from 3.3 to 5.9) when both psychotropic and nonpsychotropic medications were taken into account.”
InfluentialReporting bias in medical research - a narrative review
McGauran, N., Wieseler, B., Kreis, J., Schüler, Y.-B., Kölsch, H., & Kaiser, T. (2010) · Trials · doi:10.1186/1745-6215-11-37 · Cited by 452
Demographic and Clinical Characteristics of Individuals in a Bipolar Disorder Case Registry
Kupfer, D. J., Frank, E., Grochocinski, V. J., Cluss, P. A., Houck, P. R., & Stapf, D. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0206 · Cited by 294
Factors associated with treatment nonadherence among US bipolar disorder patients
Baldessarini, R. J., Perry, R., & Pike, J. (2008) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.908 · Cited by 198
Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview
Dias, V. V., Balanzá‐Martinez, V., Soeiro‐de‐Souza, M. G., Moreno, R. A., Figueira, M. L., Machado‐Vieira, R., & Vieta, E. (2012) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2012.01910.x · Cited by 146
Find Duplicates among the PubMed, EMBASE, and Cochrane Library Databases in Systematic Review
Qi, X., Yang, M., Ren, W., Jia, J., Wang, J., Han, G., & Fan, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071838 · Cited by 98
Polytherapy in Bipolar Disorder
Lin, D., Mok, H., & Yatham, L. N. (2006) · CNS Drugs · doi:10.2165/00023210-200620010-00003 · Cited by 91 · cited 7×
“Accounting of additional psychotropic and nonpsychotropic medications beyond the sole, seven-core medications regarded by the STEP-BD study (namely lithium, divalproex, carbamazepine, lamotrigine, and other anticonvulsants without definitely established thymoleptic properties as topiramate, gabapentin; oxcarbazepine,…”
InfluentialMajor Depression and Mental Health Care Utilization in Canada: 1994 to 2000
Patten, S. B., & Beck, C. A. (2004) · The Canadian Journal of Psychiatry · doi:10.1177/070674370404900505 · Cited by 75
Ghaemi, S. N. (2002) · doi:10.1201/b15278 · Cited by 48
Cited by
Fornaro, M., Anastasia, A., Novello, S., Fusco, A., Solmi, M., Monaco, F., Veronese, N., De Berardis, D., & de Bartolomeis, A. (2018) · Bipolar Disorders · doi:10.1111/bdi.12612 · Cited by 93
Self-citationFornaro, M., Stubbs, B., De Berardis, D., Perna, G., Valchera, A., Veronese, N., Solmi, M., & Ganança, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17020241 · Cited by 53
Self-citationKumar, R., Nuñez, N. A., Prokop, L. J., Veldic, M., Betcher, H., & Singh, B. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001475 · Cited by 16
Metadata
- Authors
- Fornaro, M., De Berardis, D., Koshy, A., Perna, G., Vancampfort, D., Stubbs, B., & Valchera, A.
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2016-03
- Volume
- 12
- Pages
- 719
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- OpenAlex
- W2320387752
- Cited by
- 115
- References
- 11
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.